Using nanotechnology to improve the characteristics of antineoplastic drugs: Improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel

Foote, MaryAnn

doi:10.1016/s1387-2656(07)13012-x

Cited by 48 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nab-paclitaxel capitalizes upon albumin binding to its receptor (gp60) on endothelial cells, which initiates transcytosis across the endothelial cell into the extravascular space via caveolae (43)(44)(45) and then into tumor cells mediated by secreted protein acidic rich in cysteine (SPARC; ref. 46).…”

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

Naing

Moulder

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Because liver involvement in patients with metastatic cancer has limited options and poor outcomes, we conducted a phase I study to determine the safety, activity, and pharmacokinetic characteristics of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel (HAI nab-paclitaxel). Cohorts of three patients having predominant hepatic metastases received HAI nab-paclitaxel at three dose levels (180, 220, and 260 mg/m 2 , respectively) infused for more than 1 hour every 3 weeks (3 þ 3 design). Some patients participated in comparative pharmacokinetic studies (i.v. vs. HAI), receiving their first course i.v., to determine peak concentrations and effect of first-pass hepatic extraction compared with subsequent courses administered by HAI. The highest dose level was expanded to determine the safety and activity of HAI nabpaclitaxel. Thirty-eight patients were treated. There were no dose-limiting toxicities at doses up to 260 mg/m 2 . Common adverse events included alopecia, fatigue, myelosuppresion, nausea, and vomiting. Three patients had stable disease for 4 or more months and 2 patients (1 of 12 with breast cancer and 1 of 1 with cervical cancer) achieved a partial response lasting for 5 and 15 months, respectively. Peak concentrations were lower ($50%) with greater hepatic extraction of drug ($42%) following HAI than i.v. infusion based on area under the curve comparison of drug exposure. HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m 2 or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases. Mol Cancer Ther; 10(7); 1300-7. '2011 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

Naing

Moulder

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Substitution of Therapy A new formulation of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) avoids the use of Kolliphor as a vehicle, and thus premedication is not required 61,62 . No hypersensitivity reactions were reported in several phase i, ii, and iii studies that used this agent 28,[62][63][64] , and administration of nab-paclitaxel was well tolerated in 5 patients who had previously experienced hypersensitivity reactions to paclitaxel 65 .…”

Section: 34mentioning

confidence: 99%

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

et al. 2014

View full text Add to dashboard Cite

“…SPARCalbumin interaction supports the accumulation of albumin in tumor and increases the effectiveness of albumin-bound paclitaxel (nab-paclitaxel). The success of nab nanoparticles has paved a way for their use in different types of cancer, and a large number of clinical trials, utilizing these nanoparticles, are presently in progress [43,[67][68][69][70]]. …”

Section: Targeted Therapy Of Cancermentioning

confidence: 99%

Nanoparticulate systems as drug carriers: the need

Patravale¹,

Dandekar²,

Jain³

2012

Nanoparticulate Drug Delivery

View full text Add to dashboard Cite

Using nanotechnology to improve the characteristics of antineoplastic drugs: Improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel

Cited by 48 publications

References 38 publications

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

Nanoparticulate systems as drug carriers: the need

Contact Info

Product

Resources

About